Invest in ImmunoGen, Inc. on Stash

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.

To buy fractional shares

of ImmunoGen, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

ImmunoGen, Inc.

Ticker: IMGN

ImmunoGen, Inc.

$15.09

+10.39%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years.

IMGN Performance Breakdown

Share Price

$15.09

Today's change

5.01%

Year to date change (YTD)

216.35%

Dividend yield

N/A

Last dividend paid

N/A

Last dividend pay date

N/A

About IMGN

ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Mirvetuximab soravtansine is a first-in-class ADC targeting folate receptor alpha (FRα), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. IMGN632 (Pivekimab sunirine) is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. It is advancing pivekimab in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

ImmunoGen, Inc. Stock Ticker

IMGN

For more information

https://www.immunogen.com

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years.

Certain companies are volatile.

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,8 recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.1

Learn how to invest

Get professional advice and education at every step.

How to buy ImmunoGen, Inc. stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Stash offers two subscription plans: Stash Growth and Stash+.

Once your market order of ImmunoGen, Inc. stock is complete, you'll officially be a shareholder of ImmunoGen, Inc.!

Invest in ImmunoGen, Inc. on Stash

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.

To buy fractional shares

of ImmunoGen, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Subscribe to The Wallet!

Looking for financial guidance? Check your Wallet. Every week, your inbox will be packed with market savviness and clever money management techniques. Sign up today!

By using this website you agree to our Terms of Use and Privacy Policy.

Ready to start
building wealth?

By using this website you agree to our Terms of Use and Privacy Policy.